chevron_leftBack
As of 13 June 2026, Nuvectis Pharma, Inc. has a market cap of $225.18M USD, ranking #20339 globally and #3345 in the United States.
It ranks #1826 in the Healthcare sector, and #664 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$225.18MUSD
Enterprise Value
$196.99MUSD
Net Income (TTM)
-$28.87MUSD
PB Ratio
12.1
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Ron Bentsur
open_in_new
Employees
13
Founded
2020
IPO
04 Feb 2022
Website
nuvectis.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -2.2% | -0.1% | 15% | 2.4% | 33% | -20% |
News
Loading...
NVCT Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
NVCT
Nuvectis Pharma Inc
ISIN: US67080T1088
Shares Out.:
Shares Outstanding:
26.526M1
Shares Float:
15.489M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
8.50 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
338K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
243K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
160K%
|
97.4
|
|
NYSE: MRK
|
$274.03B
122K%
|
15.1
|
|
NYSE: PFE
|
$149.38B
66K%
|
19.5
|
|
NYSE: BMY
|
$117.58B
52K%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$321.52B
143K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
128K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
122K%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$181.82B
81K%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$110.1B
49K%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$108.46B
48K%
80.96B GBP
|
14.6
|
chevron_leftBack